Total: $452.95M | ||||
Company |
Type Of Financing |
Number Of Shares, Units Or Warrants (M) |
Amount Raised (M) |
Investors; |
| | ||||
Aerogen Inc. (AEGN) |
Convertible debt deal |
N/A |
$0.51 |
The Carpenter Family Trust purchased the convertible debenture, which bears interest of 10% and is due March 1, 2004; the conversion price is $3.044 per share; the trust also got a four-year war- rant to buy another 82,129 shares at $3.044 (1/26) |
AspenBio Inc (OTC BB:APNB) |
Private placement of stock |
1.08S |
$1.08 |
AspenBio sold about 1.08M shares at $1 each; Berry Shino Securities was placement agent (1/7) |
AVI BioPharma Inc. (AVII) |
Warrants exercise |
1.62S 0.39W |
$7.5 |
Investors in a direct equity placement in December exercised their option to buy 1.62M more shares at $4.62 each; they got new warrants to buy 389,611 more shares at $5.50 each; Rodman & Renshaw was placement agent (1/27) |
Axonyx Inc. (AXYX) |
Private placement of stock and warrants |
65S and 2.41W |
$50 |
Axonyx raised $50M through the sale of 9.65M shares at $5.15 per share and warrants to purchase 2.41M shares at $7.25 each; Rodman & Renshaw was the lead placement agent; Punk Ziegel & Co. was financial adviser and a placement agent (1/8) |
Callisto Pharmaceuticals Inc. (OTC BB:CLSP) |
Private placement of stock |
3.9S |
$5.86 |
Details on the financing were not disclosed (1/21) |
Cellegy Pharmaceuticals Inc. (CLGY) |
Equity financing agreement |
3.74S and 0.26W |
$15 |
Cellegy entered a deal under which Kingsbridge Capital Ltd. will buy 3.74M shares over two years; the stock will be sold at a discount of about 10%, s the value will be based on the price at the time of the sale; Kingsbridge also got warrants to purchase 260,000 shares at $5.27 per share (1/16) |
Corautus Genetics Inc. (AMEX:CAQ) |
Private placement of stock and warrants |
1.2S and 0.24W |
$5.26 |
Corautus sold 1.2M shares at 90% of the average closing price over 20 days to Vertical Ventures LLC, four investment funds and an account managed by Ardsley Partners; investors also got warrants for the purchase of 240,000 shares at $6.72 each (1/21) |
Corautus Genetics Inc. (AMEX:CAQ) |
Convertible debt facility |
N/A |
$2.5 |
Corautus received a $2.5M loan facility from Boston Scientific Corp. under a loan agreement they entered in July 2003 (1/13) |
Corautus Genetics Inc. (AMEX:CAQ) |
Private placement of stock and warrants |
0.542S and 0.108 |
$2.15 |
Corautus raised $2.15M through the sale of 541,690 shares at 90% of the share price at the time of the deal, and warrants for 108,338 shares exercisable $5.4375 per share; the private investor who helped arrange the deal also got a warrant for 22,067 shares exercisable at $1 each (1/12) |
Cortex Pharmaceuticals Inc. (AMEX:COR) |
Private placement of stock and warrants |
6.9S and 4.49W |
$19 |
Cortex sold 6.9M shares at $2.75 each and 4.49M five-year warrants exercisable at $3.25 per share; Rodman & Renshaw Inc. was placement agent (1/9) |
Forbes Medi-Tech Inc. (Canada; FMTI) |
Private placement of stock and warrants |
5.375S and 1.61W |
$10.75 |
Forbes sold 5.375 million Series A voting convert- ible preferred shares at $2 per share, each convertible into one common share, and 1.61M warrants convertible at $2.40 for three years; investors included Great Point Partners LLC and Biotechnology Development Fund IV LP (1/7) |
Genaera Corp. (GENR) |
Direct equity placement |
4.95S and 0.990W |
$20 |
The stock was sold at $4.04 per share, a 10% discount, to four unnamed institutional investors; the warrants have an exercise price of $5.38 per share (1/22) |
Generex Biotechnology Corp. (GNBT) |
Private placement of stock and warrants |
1.7S and 0.425W |
$2.5 |
Generex sold 1.7M shares of stock and warrants to purchase 425,170 shares at $1.86 each; the price was based on the Dec. 18 closing price, plus consideration of 4 cents for the warrants; institutional investors participated (1/6) |
GenoMed Inc. (OTC BB:GMED) |
Private sale of stock |
ND |
$0.9 |
GenoMed secured an equity investment of $900,000 from Advanced Optics Electronics Inc., which will get restricted common shares at a 25% discount (1/20) |
GlycoGenesys Inc. (GLGS) |
Private placement of stock and warrants |
3.45S and 0.962W |
$4.3 |
GlycoGenesys issued 3.45M shares at $1.25 each and warrants to purchase 962,000 shares at $2.70 for five years; investors also got warrants for 1.38M and 340,000 shares at an exercise price of $1.25 and $1.47, respectively, exercisable for 60 days following the effectiveness of a registration statement (1/08) |
Immtech International Inc. (AMEX:IMM) |
Private placement of equity |
N/A |
$5 |
Immtech sold 200,000 shares of Series D convertible preferred at $25 per unit to private investors; terms of the deal were not disclosed (1/26) |
Immunomedics Inc. (IMMU) |
Sale of convertible notes |
N/A |
$10 |
Immunomedics sold $10M of two-year convertible senior notes with a 3.25% interest rate; the notes are convertible at the greater of 120% of the average price for the five business days after the trade date or $5.33 per share; the buyers have a six-month option on another $3M in notes (1/13) |
Inyx Inc. (OTC BB:IYXI) |
Credit facility |
N/A |
$3.5 |
Inyx secured a $3.5M credit facility from Laurus Master Fund Ltd.; Inyx issued a revolving three- year convertible note to Laurus that bears interest at the greater of prime, plus 3% or 7% (1/6) |
Lynx Therapeutics Inc. (LYNX) |
Private placement of stock and warrants |
0.8S and 0.2W |
$4 |
Lynx sold 800,000 shares of common stock at $5 per share and issued warrants to purchase 200,000 shares at $6.25 per share; the sale was made to institutional investors and the price represented a 10-day average (1/2) |
Manhattan Pharmaceuticals Inc. (OTC BB:MHTT) |
Private placement of stock |
3.37S |
$3.7 |
Manhattan raised $3.7M from the sale of about 3.37M shares; the financing was completed by Paramount Capital Inc. (1/13) |
Medical Discoveries Inc. (OTB BB:MLSC) |
Private placement of restricted stock |
ND |
$1.1 |
Medical Discoveries raised $1.1M through the sale of restricted stock; details were not disclosed (1/21) |
Northfield Laboratories Inc. (NFLD) |
Registered direct offering |
2.6S |
$15.08 |
Northfield is selling the stock at $5.80 per share to accredited investors, who have a 90-day option to purchase another 600,000 shares at the same price; SG Cowen Securities Corp. was placement agent (1/26) |
NovaDel Pharma Inc. (OTC BB:NVDL) |
Private placement of stock and warrants |
13.3S and 4W |
$14 |
NovaDel raised $14M through the sale of about 13.3M shares and warrants to purchase 4M shares under undisclosed terms; Paramount Capital Inc. was placement agent (1/12) |
OxiGene Inc. (OXGN) |
Private placement of stock |
2.76S |
$24.2 |
OxiGene sold about 2.76M shares at $8.78 each in a private sale to institutional investors; Lehman Brothers was lead placement agent, and Rodman & Renshaw Inc. and Roth Capital Partners LLC were co-placement agents; Lazard Freres served as financial adviser; the shares were sold from a shelf registration (1/14) |
Palatin Technologies Inc. (AMEX:PTN) |
Private placement of stock and warrants |
7S and 1.05W |
$22.75 |
Palatin raised $22.75M by selling shares at $3.25 each and warrants exercisable at $4.06 each; investors were Alexandra Investment Management, Lurie Investments Inc., Albert Fried & Co., Elliott Associates LP, Perry Partners Inter- national Inc., Deutsche Bank AG London, Clariden Biotechnology Equity Fund and Lombard Odier Darier Hentsch & Co.; CIBC World Markets Corp. was lead placement agent and Legg Mason Wood Walker was co-agent (1/30) |
Pharming Group NV (the Netherlands; OTC BB:PHGUF) |
Private placement of stock and warrants |
18S and 2.7W |
€25 (US$31.78) |
Pharming reached agreements to sell shares at a 20-day average price of €1.40; investors got one-year warrants to purchase another 2.7M shares at €2 each; at the same time, debt of €5.8M is being converted to equity (1/19) |
Pharmos Corp. (PARS) |
Firm- commitment underwritten deal |
1.575S |
$4.33 |
Underwriters of a financing in December exercised an option on another 1.575 shares at $2.75 per share; the deal totaled about 12.08M shares and $33.2M in gross proceeds; underwriters were C.E. Unterberg, Towbin and Harris Nesbitt Gerard (1/5) |
Pluristem Life Systems Inc. (Israel; OTC BB:PLRS) |
Private placement of equity |
ND |
$1.5 |
The deal was made with individual and institutional investors; details were not disclosed (1/21) |
Questcor Pharmaceuticals Inc. (AMEX:QSC) |
Private stock deal |
4.88S |
$2.4 |
Questcor agreed to sell existing investors 4.88M shares in exchange for $2.4M and the retirement of warrants to purchase 3.88M shares; investors were Broadwood Capital, Craig Drill Capital, Promed Management LLC, SF Capital Partners, Defiante Farmaceutica Lda, Midsummer Capital and others (1/16) |
RegeneRx Biopharmaceuticals Inc. (OTC BB:RGRX) |
Private placement of stock and warrants |
2.4S and 0.60W |
$2.3 |
RegenerRx sold the shares at 95 cents each to Defiante Farmaceutica Lda, with which the company has a licensing deal, and other investors; the 30-month warrants are exercisable at $1.50 per share (1/23) |
Sepracor Inc. (SEPR) |
Private sale of convertible notes |
N/A |
$150 |
Investors in a sale of $600M of notes in December exercised their option to buy another $150M in notes; the deal involved the sale of 0% convertible senior subordinated notes due in 2008 and 2010 (1/16) |
V.I. Technologies Inc. (VITX) |
Private placement of stock and warrants |
2.96S and 1.92W |
$3.4 |
V.I. Technologies expanded a $6.6M financing through the sale of 2.96M shares at $1.15 each to institutional investors; the investors also get warrants for 739,000 shares exercisable at the same price and 1.18M warrants exercisable for four years at $1.75 each; SG Cowen Securities Corp. was exclusive placement agent (1/30) |
V.I. Technologies Inc. (VITX) |
Private placement of stock and warrants |
7.33S and 2.93W |
$6.6 |
V.I. Technologies sold about 7.33M shares at 90 cents each; investors also got four-year warrants allowing them to purchase another 2.93M shares at $1.32 each; also, investors have a five-month option to purchase another 1.83M shares at 90 cents each; SG Cowen Securities Corp. was exclusive placement agent (1/14) |
| | ||||
Notes: | ||||
This chart does not include real estate or manufacturing plant financings. | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
@ Dates refer to the date of the press release. | ||||
N/A = Not available, applicable or reported; ND = Not disclosed. | ||||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board. | ||||
